Crescent Biopharma (CBIO) vs Kamada (KMDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Crescent Biopharma (CBIO) has outperformed Kamada (KMDA) over the past year, gaining 19.5% versus a gain of 18.6%. Over five years, KMDA leads with a +49.7% price change compared with -93.2% for CBIO. Crescent Biopharma is the larger company by market cap ($501.1 million vs $455.3 million), about 1.1 times the size.
Kamada pays a dividend yielding 3.17%, while Crescent Biopharma does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBIO | KMDA |
|---|---|---|
| Share price | $13.49 | $7.89 |
| Market cap | $501.11M | $455.33M |
| 1-day change | -0.59% | -2.71% |
| YTD return | +13.74% | +11.76% |
| 1-year return | +19.49% | +18.65% |
| 5-year return | -93.19% | +49.72% |
| P/E ratio (TTM) | — | 21.32 |
| Forward P/E | — | 13.68 |
| EPS (TTM) | $-7.63 | $0.37 |
| Dividend yield | 0.00% | 3.17% |
| Annual dividend | $0.00 | $0.25 |
| 52-week high | $27.41 | $9.35 |
| 52-week low | $8.72 | $6.55 |
| Distance from 52-week high | -50.78% | -15.61% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +133.51% | +71.10% |
| Average volume | 387.23K | 118.76K |
| Shares outstanding | 37.14M | 57.71M |
| Employees | 69 | 462 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Kamada offers a meaningfully higher dividend yield (3.17% vs 0.00%).
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Healthcare · Biotechnology · 69 employees
About Kamada
KMDA stock →Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Healthcare · Drug Manufacturers - Specialty & Generic · 462 employees
CBIO vs KMDA FAQ
Which is bigger, Crescent Biopharma or Kamada?
Crescent Biopharma (CBIO) is larger, with a market capitalization of $501.11M compared with $455.33M for Kamada (KMDA).
Which stock has performed better over the past year, CBIO or KMDA?
CBIO returned +19.49% over the past 12 months, compared with +18.65% for KMDA (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Crescent Biopharma or Kamada?
Kamada pays a dividend yielding 3.17%, while Crescent Biopharma does not currently pay a regular dividend.
Are Crescent Biopharma and Kamada in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Crescent Biopharma and Drug Manufacturers - Specialty & Generic for Kamada.